PET Imaging of Dopamine in Healthy Study Participants
PET Imaging of Dopamine D2 Receptors and Extracellular Dopamine With (18F)Fallypride, D-amphetamine, and Alpha-Methyl-Para-Tyrosine in Healthy Subjects
2 other identifiers
interventional
45
1 country
1
Brief Summary
The purpose of this study is to measure molecules on or in cells that interact with a chemical in the nervous system, called dopamine. Investigators will obtain two kinds of images of the brain-a position emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Thirty-eight participants aged 18 to 45 will be enrolled in this study. They must have no history of medical or psychiatric illness, including substance abuse. Participants will have four appointments at NIH. On the first visit, they will undergo a physical exam, a medical history, and lab tests. The second and third visits will involve PET scans and the fourth visit will involve an MRI scan. Participants will be compensated up to $430 for their involvement in this study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_2 healthy
Started Jun 2003
Longer than P75 for phase_2 healthy
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 17, 2003
CompletedStudy Start
First participant enrolled
June 17, 2003
CompletedFirst Posted
Study publicly available on registry
June 18, 2003
CompletedStudy Completion
Last participant's last visit for all outcomes
August 15, 2007
CompletedJuly 2, 2017
August 15, 2007
June 17, 2003
June 30, 2017
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Age 18-45, inclusive
- In good general health on basis of history and physical examination
- Normal screening laboratory studies including thyroid function tests, blood count, serum electrolytes, liver and kidney function, and urinalysis
- Normal ECG at a resting condition
- Normal blood pressure
- No illegal drug use based on urine drug screen
You may not qualify if:
- Pregnancy/Nursing
- Evidence of active mental or neurological illness
- Medically significant biochemical or hematological abnormality on screening laboratory studies
- Abnormal ECG
- High Blood Pressure (above 140 systolic and/or above 90 dystolic pressure)
- History of myocardial infarction or angina pectoris
- Positive urine drug screen or use of alcohol within one week prior to each PET study
- History of substance abuse or dependence within 6 months
- Presence of ferromagnetic metal in the body or heart pacemaker
- Body weight more than 93 kg to limit AMPT dose to 4 g/ day (only for subjects having four PET scans and d-amphetamine and AMPT administration)
- Claustrophobia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Related Publications (1)
Anand A, Verhoeff P, Seneca N, Zoghbi SS, Seibyl JP, Charney DS, Innis RB. Brain SPECT imaging of amphetamine-induced dopamine release in euthymic bipolar disorder patients. Am J Psychiatry. 2000 Jul;157(7):1108-14. doi: 10.1176/appi.ajp.157.7.1108.
PMID: 10873919BACKGROUND
MeSH Terms
Interventions
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Purpose
- TREATMENT
- Sponsor Type
- NIH
Study Record Dates
First Submitted
June 17, 2003
First Posted
June 18, 2003
Study Start
June 17, 2003
Study Completion
August 15, 2007
Last Updated
July 2, 2017
Record last verified: 2007-08-15